Category: by publisher

Journal corrects, but will not retract, controversial paper on internet porn

Gary Wilson

Dismissing concerns of the Committee on Publication Ethics and extensive allegations of misconduct, a journal has corrected, but is refusing to retract, a 2016 paper linking online pornography to sexual dysfunction in men.
The article, “Is internet pornography causing sexual dysfunctions? A review with clinical reports,” appeared last year in Behavioral Sciences, which is published by MDPI.
After publication, critics asked COPE to look at the paper, and in particular whether the authors had obtained adequate informed consent for two patients described in the work. COPE, which has no enforcement authority, said in an email to the publisher that it would have recommended retraction of the article.

Continue reading Journal corrects, but will not retract, controversial paper on internet porn

Journals flag two papers by prominent researcher — who is also on trial for domestic abuse

Adeel Safdar was once a rising star in the field of kinesiology. After completing his doctorate degree at McMaster University in Canada, working with one of the titans of his field, Safdar took a postdoc at Harvard, then accepted a newly created chair position at another university in Ontario.

That all came crashing down last year, when Safdar went on trial in Canada, accused of horrifically abusing his wife. Over the course of the trial, allegations arose about his research, prompting two journals to flag papers he co-authored with his former mentor, Mark Tarnopolsky.

Tarnopolsky — author of more than 400 papers, which have collectively been cited more than 17,000 times, according to Clarivate Analytics’ Web of Science — told Retraction Watch:

Continue reading Journals flag two papers by prominent researcher — who is also on trial for domestic abuse

Karolinska told a journal to retract a paper by Macchiarini. It refused. The story didn’t end there.

The president of the Karolinska Institutet (KI) is frustrated.

At the beginning of the year, Ole Petter Ottersen informed a journal that one of its papers — co-authored by former superstar Paolo Macchiarini — had been tainted by misconduct. But the journal declined to retract it.

Despite the fact that KI had conducted its own investigation into the integrity of the paper, the journal Respiration argued that it was “not in a position to make a judgement on whether or not to retract this article.” Instead, it proposed publishing KI’s argument for why the paper should be retracted, along with a rebuttal from the authors.

To Ottersen, this is just wrong. Yesterday, he posted some of his correspondence with the journal, which includes his request for retraction, the journal’s response, and his rebuttal. Ottersen’s blog post concludes:

Continue reading Karolinska told a journal to retract a paper by Macchiarini. It refused. The story didn’t end there.

Misconduct probe of once rising star prompts retraction of cat’s meow paper

A group of Australian researchers who studied the cat’s meow as a model for urinary incontinence and other motor-neural issues in people have lost a 2015 paper in the wake of a misconduct investigation.

The target of the inquiry was Hari Subramanian, a former senior research fellow at the Queensland Brain Institute, part of the University of Queensland (UQ). Subramanian was leading studies of incontinence in the elderly, for which he sometimes used nerve stimulators on live rodents and cats. As The Australian reported last September, animal rights activists have objected to his research methods — which sometimes involved sticking probes into the brains of living animals.  

Recently, the school launched an investigation — prompted by an unknown complainant — into the integrity of Subramanian’s data in two articles, including one, now retracted, that appeared in the Journal of Comparative Neurology.  

The case is controversial, to say the least, replete with allegations of unfair attacks. Subramanian’s lawyer told us the journal may be reviewing its decision to retract the paper. (We couldn’t confirm that with the editor.)

Here’s what we’ve found out so far.

Continue reading Misconduct probe of once rising star prompts retraction of cat’s meow paper

How much cancer stems from diabetes, obesity? Lancet journal swaps high-profile paper

Six months ago, the media was ablaze with the findings of a new paper, showing that nearly six percent of cancer cases are caused, at least in part, by obesity and diabetes. But this week, the journal retracted that paper — and replaced it with a revised version.

The new paper doesn’t change the main findings much — the share of all cancers attributable to diabetes and obesity changed from 5.6% to 5.7%, which wouldn’t change any headlines about the original paper. But soon after the paper was published, a group of researchers noticed the authors’ mistake — which was significant enough to prompt the journal to retract the paper entirely, and swap it with a new one.

According to first author Jonathan Pearson-Stuttard at Imperial College London:

Continue reading How much cancer stems from diabetes, obesity? Lancet journal swaps high-profile paper

Dental journal pulls a dozen papers for recycled images and “unreliable data”

A leading orthodontics journal has retracted 12 papers after determining that they contained either reused images, questionable data or both. Several of the articles involved experiments conducted in dogs — and one person familiar with the case told us that the duplication was an attempt to avoid sacrificing more animals than necessary for the research.  

Although the list of authors on the articles varies, the common denominator is Jose Luis Calvo-Guirado, of the UCAM Universidad Católica San Antonio de Murcia, in Spain. Calvo-Guirado’s title at the institution is director de la Cátedra Internacional de Investigación en Odontología, which Google translates as director of the International Research Chair in Dentistry.  Calvo-Guirado also holds (or has held) a research professorship at SUNY Stony Brook in the Department of Prosthodontics and Digital Medicine, according to his CV.

Calvo-Guirado’s name is on at least 187 entries in PubMed. Of those, 40 appeared in Clinical Oral Implants Research, a Wiley title on whose editorial board the researcher served, according to his CV.  

Continue reading Dental journal pulls a dozen papers for recycled images and “unreliable data”

Hey journals, it is possible to quickly correct the record

Even when a paper is obviously flawed, it can take years for journals to take action. Some never do. But it doesn’t have to be that way.

On April 27, a reader emailed the editors of two journals, noting that each had recently published a paper by the same group of authors that appeared strikingly similar.

Four days later, on May 1, a representative at Medicine, the journal that published the most recent version of the paper, wrote the reader back, saying the paper was going to be retracted.

Continue reading Hey journals, it is possible to quickly correct the record

Now-retracted chem paper’s problems “should have been noticed by the referees,” group says

Last year, chemist Marcus Tius at the University of Hawaii saw a paper describing the synthesis of some organic compounds, and was “struck by the implausibility” of the reported structures. So he joined up with some colleagues to try to replicate the data.

While Tius and his team were trying to repeat the experiment, however, in December 2017 the journal — Organic Letters — retracted the paper. The journal, published by the American Chemical Society, noted that the authors had not been able to produce crystal structures that confirm they had synthesized those compounds in particular. So Tius and his colleagues knew they couldn’t replicate the findings — but carried on their experiment anyway:

Continue reading Now-retracted chem paper’s problems “should have been noticed by the referees,” group says

Caught Our Notice: A paper mistakenly ID’d a patient. Its retraction notice did, too. (Oops!)

What Caught Our Attention: Last year, a journal retracted a paper about a child who developed a rare complication related to the inherited disorder Gaucher Disease, after realizing it had inadvertently identified the child. It wasn’t an immediately obvious mistake — the authors listed the drugs the patient was taking, and in the case of one drug, there was only one child in the world taking it. For anyone in the know, that would make the child’s identity clear.

So retracting the paper makes sense — but publishing a retraction notice that spells out the issue in detail, including the name of the drug and the fact the patient was the only pediatric recipient, did not. So last month, the Journal of Pediatric Hematology/Oncology corrected the retraction notice, removing the name of the drug. (Phew.)

Continue reading Caught Our Notice: A paper mistakenly ID’d a patient. Its retraction notice did, too. (Oops!)

A distorted record on blood pressure drugs: Why one group is trying to clean up the literature

In 2015, a group of researchers based in Spain decided to write a review article on high blood pressure. But when they looked over eight articles co-authored by the same person, they noticed some undeniable similarities.

Over the last few years, Giuseppe Derosa, based at the University of Pavia in Italy, has racked up 10 retractions after journals determined he’d published the same material multiple times. But there’s much more to this story: The researchers in Spain (led by Luis Carlos Saiz of the Navarre Regional Health Service in Pamplona) kept digging into his publication record, and have since identified dozens of additional potential duplicates. Although the outside researchers alerted journals to the additional potentially problematic papers in 2015, most have not taken action; recently, two journals published by Taylor & Francis flagged 12 of Derosa’s articles, three of which they had been alerted about in 2015 by Saiz and colleagues.

Now, Saiz is telling his story — and why duplication of medical research matters:

Continue reading A distorted record on blood pressure drugs: Why one group is trying to clean up the literature